Differential gene expression of two-pore-domain potassium channels in malignant pleural mesothelioma Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013
Over-expression of chloride intracellular channels (CLICs) 3 and 4 in malignant pleural mesothelioma Source: Annual Congress 2013 –Diagnosis and management of pleural and mediastinal diseases Year: 2013
Effect of asbestos on gene expression of tight junctions components in malignant pleural mesothelioma Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016
Comparison between mesothelin and fibulin-3 detection in pleural malignant mesothelioma (MPM) patients Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016
Down-regulation of retinoid receptors in malignant mesotheliomas Source: Eur Respir J 2001; 18: Suppl. 33, 17s Year: 2001
Role of fibulin-3 in the diagnosis of malignant mesothelioma Source: International Congress 2014 – Diagnosis and treatment of pleural mesothelioma Year: 2014
Expression of c-met in malignant pleural mesothelioma; an immunohistochemical study Source: Annual Congress 2007 - Inorganic dust "old timers and new kids on the block" Year: 2007
Activated KRAS signaling triggers malignant pleural effusion Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015
Detection of mesothelin in the pleural effusion has a higher diagnostic utility than in serum for diagnostic of malignant mesothelioma Source: Annual Congress 2013 –Clinical problems in mediastinal and pleural malignacies Year: 2013
Expression of human mammaglobin gene in pleural effusion of patients affected by malignant pleural mesothelioma (MM) Source: Eur Respir J 2004; 24: Suppl. 48, 81s Year: 2004
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer Source: Eur Respir J 2012; 39: 677-684 Year: 2012
Targeting of CSF1R abrogates Lewis Lung adenocarcinoma-induced malignant pleural effusion Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management Year: 2018
Diagnostic value of pleural fluid angiopoietin-2 (Ang-2) levels, to differentiate malignant pleural effusions from benign pleural effusions Source: International Congress 2016 – Mesothelioma and malignant pleural disease Year: 2016
Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: In-vitro study Source: International Congress 2015 – Emerging technologies for malignant pleural diseases management Year: 2015
Gene expression mapping to diagnose malignant mesothelioma Source: Eur Respir J 2002; 20: Suppl. 38, 232s Year: 2002
Volume quantification of malignant pleural mesothelioma Source: International Congress 2015 – Malignant pleural effusions and mesothelioma Year: 2015
Tumours of the pleura - Mesothelioma Source: Respipedia Article Year: 2017
Role of tumor derived versican in experimental malignant pleural mesothelioma Source: International Congress 2016 – Mesothelioma and pleural disease: from the bench to the bedside Year: 2016
Differential diagnostic efficiency of T cells subsets versus interferon-gamma, tumor necrosis factor alpha and adenosine deaminase in distinguishing tuberculous from malignant pleural effusions Source: International Congress 2016 – Tuberculosis: immune responses of CD8+ T cells, value of interferon-gamma and other cytokines, Th2 responses, BCG, and biomarkers Year: 2016
CXCL12 expression in malignant mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 138s Year: 2007